Value
5.2/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 1.7 |
| Analyst target | 7.5 |
HTFL · Why this verdict
Why Heartflow (HTFL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is negative at -25% of revenue and operating margins are deeply negative at -157.9%, meaning the company is consuming cash at a pace that raises questions about the long-term sustainability of the current cost structure without continued external financing. Warnings | Operating margin should improve above -50% and free cash flow should narrow to within -10% of revenue over the next four quarters for the quality concern to begin meaningfully resolving. | →Stable |
| CounterWith revenue growing at 41% year-over-year, the cash consumption may reflect investment in scaling a rapidly expanding business; if the growth trajectory holds, there is a credible path toward profitability that the current cash position does not foreclose. | ||
With approximately 98% of revenue derived from a single product, the company has virtually no revenue diversification, leaving the business acutely exposed to any disruption — competitive, clinical, or commercial — to that one offering. Bear case | If concentration is being resolved, revenue from products other than the core offering should cross 10% of total quarterly sales within the next four quarters. | →Stable |
| CounterA company deriving the vast majority of revenue from a single leading product can reflect market leadership rather than fragility — if adoption continues to expand and demand is durable, the concentration may represent competitive strength rather than structural risk. | ||
Revenue grew 41% year-over-year, demonstrating genuine market traction, but profitability metrics remain too weak — a Rule of 40 score of only 16, well below the 40 threshold — for the growth rate alone to translate into investable quality at the current stage. Quality breakdown | The Rule of 40 score should exceed 40 for two consecutive quarters to confirm that the business is transitioning toward efficient, margin-generative growth. | →Stable |
| CounterA Rule of 40 score of 16 while growing at 41% implies a margin drag of roughly -25 points; if margins can close even a portion of that gap as revenue scales, the quality profile could improve significantly without requiring further growth acceleration. | ||
With approximately 2.4% of headroom to the near-term price target and a risk/reward ratio of roughly 0.3-to-1 against you — with downside of 15% against limited upside — the stock is priced with essentially no appreciation buffer and the asymmetry does not favor new exposure. Price targets | For the risk/reward to reach an investable level, the price target would need to be raised by analysts to at least 15% above the current price, restoring a ratio above 1.5-to-1. | →Stable |
| CounterThe bullish technical setup — RSI at 68, MACD bullish, price above the 200-day moving average — suggests near-term buying momentum that could push the stock above resistance and trigger analyst target upgrades, improving the risk/reward without requiring a price correction. | ||
Free cash flow is negative at -25% of revenue and operating margins are deeply negative at -157.9%, meaning the company is consuming cash at a pace that raises questions about the long-term sustainability of the current cost structure without continued external financing.
→StableWarnings
- Expectation
- Operating margin should improve above -50% and free cash flow should narrow to within -10% of revenue over the next four quarters for the quality concern to begin meaningfully resolving.
CounterWith revenue growing at 41% year-over-year, the cash consumption may reflect investment in scaling a rapidly expanding business; if the growth trajectory holds, there is a credible path toward profitability that the current cash position does not foreclose.
With approximately 98% of revenue derived from a single product, the company has virtually no revenue diversification, leaving the business acutely exposed to any disruption — competitive, clinical, or commercial — to that one offering.
→StableBear case
- Expectation
- If concentration is being resolved, revenue from products other than the core offering should cross 10% of total quarterly sales within the next four quarters.
CounterA company deriving the vast majority of revenue from a single leading product can reflect market leadership rather than fragility — if adoption continues to expand and demand is durable, the concentration may represent competitive strength rather than structural risk.
Revenue grew 41% year-over-year, demonstrating genuine market traction, but profitability metrics remain too weak — a Rule of 40 score of only 16, well below the 40 threshold — for the growth rate alone to translate into investable quality at the current stage.
→StableQuality breakdown
- Expectation
- The Rule of 40 score should exceed 40 for two consecutive quarters to confirm that the business is transitioning toward efficient, margin-generative growth.
CounterA Rule of 40 score of 16 while growing at 41% implies a margin drag of roughly -25 points; if margins can close even a portion of that gap as revenue scales, the quality profile could improve significantly without requiring further growth acceleration.
With approximately 2.4% of headroom to the near-term price target and a risk/reward ratio of roughly 0.3-to-1 against you — with downside of 15% against limited upside — the stock is priced with essentially no appreciation buffer and the asymmetry does not favor new exposure.
→StablePrice targets
- Expectation
- For the risk/reward to reach an investable level, the price target would need to be raised by analysts to at least 15% above the current price, restoring a ratio above 1.5-to-1.
CounterThe bullish technical setup — RSI at 68, MACD bullish, price above the 200-day moving average — suggests near-term buying momentum that could push the stock above resistance and trigger analyst target upgrades, improving the risk/reward without requiring a price correction.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Heartflow carries 98% product concentration in a single offering, deeply negative free cash flow, and a risk/reward of roughly 0.3-to-1 against you at the current price — the combination of structural quality concerns, failed earnings delivery over the prior two quarters before recent recovery, and a bearish options posture makes the setup difficult to justify as a new or expanded position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.4 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -25% of revenue
- ▸Rule of 40: 16 (fail)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 41% YoY
Momentum
1.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 1.5 |
| Volume | 2.5 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.7 |
| Price target | 8.7 |
- ▸Light analyst coverage (7.0) — signal dampened
- ▸Analyst upside: 32%
Insider
3.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 2.0 |
| insider conviction | 2.0 |
| holder change | 5.2 |
- ▸Heavy insider selling — $62,423,982 (2.588% of mkt cap)
Peer rank
2.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.0 |
| quality rank | 0.4 |
| growth rank | 8.8 |
- ▸Industry growth leader
Technical
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.6 |
| support resistance | 9.6 |
| 52w position | 3.6 |
Risk (lower is worse)
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.5 |
| days to cover | 7.4 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| debt equity | 0.0 |
- ▸Elevated put/call: 4.21
- ▸High IV: 113%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (5)
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
- MOMENTUM:1.9<4.5
- ASYMMETRY:1.0<1.5@spot
- INSIDER:2.59%=EXTREME
Warning (0)
none
Reward-to-Risk
1.01
Upside
+15.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.4B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:1.9<4.5.
The strongest dimensions are Growth at 10.0, Sentiment at 7.6, and Technical at 7.3; the weakest are Momentum at 1.9, Risk (lower is worse) at 2.3, and Peer rank at 2.6. The V9 engine flagged 3 failed gates, producing an asymmetric reward-to-risk of 1.01 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Product Concentration Risk
Trip ifNon-core product revenues exceed 10% of total quarterly revenue for 2 consecutive quarters, meaningfully reducing single-product concentration.
- P2Negative Free Cash Flow Sustainability
Trip ifFree cash flow turns positive (FCF exceeds $0) for 2 consecutive quarters.
- P3Growth Without Investable Quality
Trip ifRule of 40 score exceeds 40 for 2 consecutive quarters.
- P4Unfavorable Risk Reward Near Ceiling
Trip ifUpside to the near-term price target exceeds 15% and the reward-to-risk ratio improves above 1.5-to-1.